OncoMatch/Clinical Trials/NCT04220749

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Is NCT04220749 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for head and neck cancer.

Phase 2RecruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT04220749Data as of May 2026

The goal of this randomized phase II study is a formal comparison of radiotherapy versus trans-oral surgery as the primary treatment of HPV-negative patients with early-stage oropharyngeal carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Biomarker criteria

Required: HPV negative

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: radiation therapy

Lab requirements

Blood counts

adequate bone marrow function, as determined by the investigator

Kidney function

adequate renal function, as determined by the investigator

Liver function

adequate hepatic function, as determined by the investigator

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify